This page lists the SEC filings reported by Orbimed Advisors.
| Type | Filed | Filer | Subject | Shares Owned | Percent Owned | |
|---|---|---|---|---|---|---|
| SC 13D/A | 2024-04-12 | ORBIMED ADVISORS LLC | Passage BIO, Inc. | 8,034,000 | 13.0% | EDGAR |
| SC 13D/A | 2024-04-04 | ORBIMED ADVISORS LLC | Enliven Therapeutics, Inc. | 8,951,463 | 19.2% | EDGAR |
| SC 13D | 2024-03-28 | ORBIMED ADVISORS LLC | Q32 Bio Inc. | 2,252,987 | 18.9% | EDGAR |
| SC 13D/A | 2024-03-22 | ORBIMED ADVISORS LLC | Compass Therapeutics, Inc. | 18,791,422 | 13.7% | EDGAR |
| SC 13D/A | 2024-03-21 | ORBIMED ADVISORS LLC | Adicet Bio, Inc. | 9,772,598 | 11.9% | EDGAR |
| SC 13D/A | 2024-03-08 | ORBIMED ADVISORS LLC | NextCure, Inc. | 1,268,013 | 4.5% | EDGAR |
| SC 13D/A | 2024-02-21 | ORBIMED ADVISORS LLC | Kinnate Biopharma Inc. | 7,559,729 | 16.1% | EDGAR |
| SC 13G/A | 2024-02-14 | ORBIMED ADVISORS LLC | Applied Therapeutics Inc. | 0 | 0.0% | EDGAR |
| SC 13G/A | 2024-02-14 | ORBIMED ADVISORS LLC | Crinetics Pharmaceuticals, Inc. | 1,667,360 | 2.5% | EDGAR |
| SC 13G/A | 2024-02-14 | ORBIMED ADVISORS LLC | Kezar Life Sciences, Inc. | 1,927,000 | 2.7% | EDGAR |
| SC 13G/A | 2024-02-14 | ORBIMED ADVISORS LLC | Mereo BioPharma Group plc | 0 | 0.0% | EDGAR |
| SC 13G/A | 2024-02-14 | ORBIMED ADVISORS LLC | Mersana Therapeutics, Inc. | 0 | 0.0% | EDGAR |
| SC 13G/A | 2024-02-14 | ORBIMED ADVISORS LLC | NeuroPace Inc | 4,003,967 | 15.2% | EDGAR |
| SC 13G/A | 2024-02-14 | ORBIMED ADVISORS LLC | Protara Therapeutics, Inc. | 0 | 0.0% | EDGAR |
| SC 13G/A | 2024-02-14 | ORBIMED ADVISORS LLC | SI-BONE, Inc. | 2,144,631 | 5.3% | EDGAR |
| SC 13G/A | 2024-02-14 | ORBIMED ADVISORS LLC | Verastem, Inc. | 1,529,115 | 6.1% | EDGAR |
| SC 13G/A | 2024-02-14 | ORBIMED ADVISORS LLC | X4 Pharmaceuticals, Inc | 11,494,437 | 6.7% | EDGAR |
| SC 13G/A | 2024-02-14 | ORBIMED ADVISORS LLC | ALX ONCOLOGY HOLDINGS INC | 2,255,000 | 4.5% | EDGAR |
| SC 13G | 2024-02-14 | ORBIMED ADVISORS LLC | Elevation Oncology, Inc. | 3,000,000 | 6.8% | EDGAR |
| SC 13G | 2024-02-14 | ORBIMED ADVISORS LLC | Scholar Rock Holding Corp | 2,960,000 | 4.1% | EDGAR |
- Form 13F-HR
- The 13F-HR report is filed quarterly to report securities held by the filer that fall under the SEC's 13F rules.
- Form SC 13D/G
- Reported by persons and groups who own 5% or more of any class of a company's outstanding shares. If the ownership changes by 1% or more, an amendment must be filed.
- Form 3, 4, and 5
- Form 3, 4, and 5 reports are filed to report insider transactions by company officers and directors, and any beneficial owners of more than ten percent of a company's shares. Form 3 is the initial report that must be filed when a person becomes an officer, director, or beneficial owner. Form 4 reports are used to report changes in ownership, while the Form 5 report is used for reporting transactions that should have been reported earlier in a Form 4 filing.